Filing Flows › Comparisons › INBX vs MGX
Inhibrx Biosciences vs Metagenomi Therapeutics: INBX and MGX compared
Inhibrx Biosciences is the larger company: $1.3M of revenue in its latest quarter (Q2 2025) against $1.2M for Metagenomi Therapeutics (Q1 2026). Inhibrx Biosciences is growing faster (13× against -70% a year earlier).
Where the money goes: INBX and MGX
Inhibrx Biosciences (INBX) · Q2 2025
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Metagenomi Therapeutics (MGX) · Q1 2026
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Inhibrx Biosciences (INBX) | Metagenomi Therapeutics (MGX) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q1 2026 |
| Revenue | $1.3M | $1.2M |
| Revenue growth, Y/Y | 13× | -70% |
| Operating margin | n/m | n/m |
| Net earnings | −$28.7M | −$23.1M |
| Operating cash flow | −$30.0M | −$21.2M |
Questions
Which is bigger, Inhibrx Biosciences or Metagenomi Therapeutics?
Inhibrx Biosciences is the larger company: $1.3M of revenue in its latest quarter (Q2 2025) against $1.2M for Metagenomi Therapeutics (Q1 2026).
Is Inhibrx Biosciences or Metagenomi Therapeutics growing faster?
Inhibrx Biosciences is growing faster (13× against -70% a year earlier).
More: Inhibrx Biosciences earnings · how Inhibrx Biosciences makes money · Metagenomi Therapeutics earnings · how Metagenomi Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2025; 10-Q filed May 11, 2026). Fiscal quarters can end on different dates. Not investment advice.